VAN LANSCHOT KEMP. EO1/ NL0000302636 /
31.05.2024 08:15:51 | Diff. +0,600 | Volumen | Geld19:37:55 | Brief19:37:55 | Marktkapitalisierung | Dividendenr. | KGV |
---|---|---|---|---|---|---|---|
37,550EUR | +1,62% | 0 Umsatz: 0.000 |
-Geld Vol: - | -Brief Vol: - | 1,6 Mrd.EUR | 5,32% | 13,33 |
GlobeNewswire
21:00
First Federal Savings Bank and ICBA Offer Tips to Help Simplify the Homebuying Process
GlobeNewswire
19:39
QuidelOrtho (QDEL) Investors Who Suffered Substantial Losses After QDEL Reported Disastrous Q4 2023 ...
GlobeNewswire
19:02
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pret...
GlobeNewswire
16:00
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstr...
GlobeNewswire
16:00
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Gli...
GlobeNewswire
16:00
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...
GlobeNewswire
15:14
Flash News: OKX Announces Position Tier Adjustments for TURBO/USDT Perpetual Futures Listing
GlobeNewswire
15:00
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Ther...
GlobeNewswire
15:00
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monothera...
GlobeNewswire
14:15
FSLY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Fastly, Inc. Investors with ...
GlobeNewswire
14:15
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
GlobeNewswire
14:05
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
- Erste Seite
- Zurück
- 1
- 2
- 3
- 4
- Weiter
- Letzte Seite